<DOC>
	<DOCNO>NCT01828294</DOCNO>
	<brief_summary>The study do patient Myasthenia Gravis ( MG ) , age 18-80 year , positive acetylcholine receptor antibody , receive great 30mg prednisone daily . Patients may may receive anticholinesterase agent . A common treatment patient disease include administration intravenous immunoglobulin ( IVIG ) , plasma protein give help maintain adequate antibody level prevent infection decrease symptom disease Myasthenia Gravis . This study do test give medication subcutaneous form ( fat abdomen , leg thighs ) well tolerate patient Myasthenia Gravis .</brief_summary>
	<brief_title>Subcutaneous Ig Maintenance Therapy Myasthenia Gravis</brief_title>
	<detailed_description>The study pilot study ascertain feasibility tolerability subcutaneous immunoglobulin ( SCIG IGSC ) maintenance therapy patient non-thymomatous MG patient ( MGFA class II-IV ) entry , age 18-80 year , positive acetylcholine receptor antibody , receive great 30mg prednisone daily . Patients may may receive anticholinesterase agent . The neurologist principal investigator site overall responsibility study performance designate medical coordinator ( MC ) . The MC ass patient sit clinic population identify potential subject inclusion exclusion criterion . Once subject identify provide informed consent participate Visit Schedule initiate . At initial visit MC perform acetylcholine receptor antibody level , record prednisone anticholinesterase dose . The MC responsible assessment adverse event . The research coordinator arrange initial laboratory test patient 's local Quest , blood drawn . Baseline lab test do include IgA level evaluate deficiency , IgG level , CBC , AchR antibody , pregnancy test woman , LFT 's , PT/PTT BUN/Creatinine . The patient complete SF-36 quality life , MG , MGFA ADL The research coordinator responsible training subject performance IGSC infusion . Subjects outpatient clinic assessment one week monthly remainder study . Patients receive 2gms/kg divide 4 week initially give 250mgs/kg/wk total 6 month . This similar standard IV treatment patient 2 gm/kg give 2-5 day initial dose . After initial dose , patient start monthly IV maintenance dose 1 gm/kg month give 1-3 day . The subject evaluate monthly assessment whether minimal manifestation ( MM ) status reach , allow reduction corticosteroid 5mg clinically indicate . The MC record adverse event symptom . The dose anticholinesterase drug decrease discretion MC . The prednisone dose decrease unless MM status lose ; situation prednisone dose increase 10mg every 2 week MM achieve . Titration prednisone cholinesterase inhibitor medication discretion physician base patient 's symptom measure symptom examination , lead determination MM . The patient complete SF-36 quality life assessment .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . AChR Ab positive myasthenia gravis ( acetylcholine receptor antibody ) . 2 . Age 1880 year . 3 . MGFA Classification IIIV ( The scale use determine severity symptom MG ) . 4 . Receiving &gt; equal 30mg Prednisone per day . 5 . No new MGspecific treatment prior 3 month . 6 . Willingness participate study protocol . 7 . QMG &gt; 10 ( quantitative myasthenia gravis score : sum grade give symptom MG ) . 8 . Treatment immunomodulator &gt; equal 3 month prior trial initiation . 1 . IgA deficiency ( major class immunoglobulins find serum external body secretion saliva , tear , sweat well gastrointestinal , respiratory , genitourinary tract ) . 2 . Previous thromboembolic event , include deep vein thrombosis , stroke myocardial infarction 3 . MGFA Class I , IV ( patient require hospitalization ) V 4 . History thymoma 5 . Thymectomy previous year planning undergo thymectomy next six month 6 . Pregnancy lactation ; unwillingness avoid pregnancy 7 . Serious concurrent medical , neurological psychiatric condition would interfere IGSC administration subsequent clinical assessment 8 . Unwillingness incapacity participate , agree necessary followup visit , give write informed consent 9 . Patients anaphylactic severe systemic reaction administration human immune globulin component Hizentra , polysorbate 80 , patient hyperprolinemia contains stabilizer Lproline 10 . Cholinesterase inhibitor 240 mg/day 11 . Body weight great 120 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>MG</keyword>
</DOC>